In this issue of Neuron, innovative new modifications to opioid receptors are used to expand the tools available to modulate neuronal activity. Vardy et al. (2015) describe a new ''DREADD'' chemogenetic tool based on the inhibitory k opioid receptor (KORD) that can be used in conjunction with already-available DREADDs. Siuda et al. (2015) report the development of ''opto-MOR,'' a light-activatable m opioid receptor (MOR) chimera that can be used to better understand the complexities of MOR signaling.
Chemogenetics and optogenetics have revolutionized neuroscience. These techniques enable us to manipulate the activity of anatomically or genetically circumscribed groups of neurons in brain and assess the physiological or behavioral consequences. As such, the direct causal contribution of specific populations of neurons to physiology or behavior can now be determined. In this issue of Neuron, two papers describe the development of innovative new chemogenetic and optogenetic tools based on clever manipulations of opioid receptor signaling that are likely to facilitate greater understanding of brain function.
In the first of these two papers, Vardy et al. (2015) describe the development of a new chemogenetic tool to modulate neuronal activity. DREADDs (designer receptors exclusively activated by designer drugs) are the best-established chemogenetics approach currently available to manipulate neuronal activity (Alexander et al., 2009; Armbruster et al., 2007; Guettier et al., 2009) . DREADDs are muscarinic acetylcholine receptors (mAChRs) that have undergone site-directed mutagenesis such that they no longer respond to their endogenous agonist (acetylcholine), but instead can be activated by clozapine-N-oxide (CNO), an otherwise biologically inert compound. The hM3Dq DREADD is derived from the excitatory M3 mAChR, whereas hM4Di is derived from the inhibitory M4 mAChR. Stimulation of hM3Dq or hM4Di by CNO increases or decreases, respectively, the excitability of neurons in which these receptors have been expressed, thereby placing their activity under experimenter control. An important limitation to currently available DREADDs is the fact that the same agonist is used to activate hM3Dq and hM4Di. As such, it is not possible to simultaneously express both receptors in the same neurons to turn on or off their activity as required, as both receptors will be activated simultaneously and have opposing actions on excitability. The same limitation applies when expressing hM3Dq and hM4Di in different groups of neurons in the same animal.
To overcome this limitation, Vardy et al. (2015) sought to develop a new DREADD whose activity can be modulated by a different ligand. To accomplish this, they took the same conceptual approach used to create hM3Dq and hM4Di, but instead of using mAChRs as the receptor substrate they used the k-opioid receptor (KOR). The endogenous agonist for KOR is the opioid peptide dynorphin A. KOR is also potently activated by salvinorin A (SALA), but not by the SALA metabolite salvinorin B (SALB), which is a relatively weak agonist at KOR (IC 50 250 nM). Indeed, SALB fails to show any of the behavioral effects commonly associated with KOR activation, such as analgesia, impairment of motor performance, or induction of an anhedonia-like aversive state, even after direct intracerebroventricular administration. Based on in silico modeling, Vardy and colleagues predicted that a specific mutation in KOR (D138N) would render it insensitive to its cognate agonist dynorphin A, but increase its sensitivity to SALB (and SALA). Mutation of KOR to incorporate this D138N substitution confirmed these predictions, rendering the receptor insensitive to dynorphin, but dramatically increasing the potency of SALB at the mutant receptor. SALB demonstrates excellent penetration into the CNS after systemic delivery and is inactive at hM3Dq, hM4Di, and a broad panel of other potential targets expressed in the CNS, all highly desirable properties in a chemogenetic ligand. Vardy and colleagues termed this new D138N-mutated KOR and SALB combination as KORD (k-opioid DREADD).
Next, the ability of KORD to modify neuronal activity in vivo and impact behavior was assessed. Vardy et al. (2015) cloned KORD into a virus vector in a double-floxed inverted orientation (DiO) such that KORD could only be expressed in the presence of Cre recombinase. They then tested the functional consequences of infusing this Cre-inducible KORD vector into the brains of mice expressing Cre in different populations of neurons with well-defined behavioral functions. Specifically, they used appropriate lines of Cre-driver mice to express KORD in GABAergic interneurons of the ventral tegmental area and substantia nigra (VTA/SN), paraventricular hypothalamus (PVH) neurons, or Agouti-related peptide (AgRP) neurons in the arcuate nucleus. Consistent with KORD-mediated inhibition of neuronal activity, they found that SALB dose-dependently increased locomotor activity in animals expressing KORD in GABAergic neurons of VTA/SN, consistent with their chemogenetic silencing (van Zessen et al., 2012) . SALB also increased feeding behavior in animals expressing KORD in PVH, specifically in SIM1 neurons, and decreased food intake in animals expressing KORD in AgRP neurons (Atasoy et al., 2012) , again consistent with KORD-mediated inhibition of targeted neurons.
Adding to this already impressive set of behavioral observations, Vardy et al. (2015) next combined the infusion of inhibitory KORD with the excitatory hM3Dq in the same neuronal populations. When KORD and hM3Dq were both expressed in GABAergic interneurons of VTA/SN they found that CNO suppressed locomotor activity and that SALB could counteract this effect. Using the same approach, they found that CNO induced hyperphagia when hM3Dq was expressed in the AgRP neurons of arcuate nucleus and that this effect was blunted by SALB when KORD was expressed in the same neurons. These exciting findings suggest that KORD can be used in combination with hM3Dq in the same animal.
It is worth noting that, although SALB did not induce any overt behavioral effects typically seen in response to KOR activation (analgesia, anhedonia), SALB remains a weak endogenous KOR agonist. It is therefore important that doses of SALB used in vivo are kept as low as possible to avoid possible activation of endogenous KORs. In addition, a more detailed understanding of the timeline and kinetics of persistent CNOhM3Dq signaling versus the more transient SALB-KORD effect will be needed to better use them in combination to manipulate neuronal activity in the most physiologically relevant manner. Nevertheless, the development of KORD is an exciting advance in the field that will permit ''multiplexing'' of DREADDs such that the activity of defined groups of neurons can be increased or decreased simultaneously or sequentially in the same animal.
In the second paper in this issue of Neuron, Siuda et al. (2015) developed a novel light-activatable m opioid receptor (MOR) that can be used to investigate the spatiotemporal dynamics of MOR signaling in vivo. Optogenetics is a powerful approach in which light-sensitive anionic or cationic channels, such as halorhodopsin and channelrhodopsin, respectively, can be expressed in discrete populations of neurons. Light of the appropriate wavelength can then be delivered to stimulate or inhibit targeted neurons.
A major strength of optogenetics is the precise temporal control that it can afford over neuronal activity, enabling endogenous patterns of cell firing to be mimicked. However, this remarkably precise, sub-second control of neuronal activity can be considered a drawback under certain circumstances. For example, many neuromodulatory systems in the brain act primarily through metabotropic, rather than ionotropic, receptors and exert slow (minutes or longer) alterations in the firing patterns of targeted neurons. For example, MORs are G protein-coupled receptors (GPCRs) that inhibit the production of intracellular second messenger systems such as cAMP. MOR activation can also modulate ionic flux across the plasma membrane by influencing the activity of G protein-gated inward rectifying potassium (GIRK) channels. Hence, opioids can induce cellular hyperpolarization and inhibit neural activity much like inhibitory light-or ligandgated ion channels, but do so according to a more gradual, but persistent, process likely to have far different functional consequences on neurons and circuits compared with the more rapid effects of ionotropic receptors (Al-Hasani and Bruchas, 2011) .
To develop an optogenetic procedure that could better recapitulate the actions of MOR on cell firing, Siuda et al. (2015) capitalized on previous work showing that hybrid GPCR constructs can be developed that render them light activatable (Airan et al., 2009) . Here, Siuda and colleagues developed a new GPCR chimera receptor by fusing the critical photoisomerizing retinal binding site of the rat rhodopsin RO4 with the intracellular components of MOR to create a hybrid light-activatable MOR, which they termed opto-MOR. They thoroughly characterized the properties of this opto-MOR to ensure that its spatial localization in cells matched that seen with native MOR. They verified that light-activated opto-MOR inhibited cAMP production and stimulated phosphorylation of extracellular signaling-regulated kinase (pERK) similar to the effects seen after agonistinduced activation of native MOR in cultured cells. They also found that opto-MOR displayed light-induced functional desensitization and internalization similar to native MOR, consistent with opto-MOR coupling to the canonical MOR machinery.
Next, Siuda et al. (2015) tested the functional consequences of light-induced activation of opto-MOR in vivo by cloning the hybrid receptor into the same type of Cre-inducible DiO virus system described above. They infused this virus into the periaqueductal gray (PAG) of mice in which Cre is expressed in inhibitory GABAergic neurons. GABAergic neurons in PAG are highly enriched in endogenous MOR. In a set of elegant experiments, they showed that opto-MOR and endogenous MOR converged onto the same intracellular signaling machineries and that stimulating native MOR with agonist could occlude light-induced opto-MOR signaling in PAG.
Finally, Siuda et al. (2015) turned their attention to the behavioral effects of light-stimulated opto-MOR activation in brain using a real-time place conditioning procedure. They infused the Cre-inducible opto-MOR virus into the rostromedial tegmental nucleus (RMTg) or ventral pallidum (VP) of the mice expressing Cre in GABAergic neurons. They found that mice demonstrated preference for an environment in which the GABAergic neurons of the RMTg were inhibited using photoactivation of opto-MOR. This is consistent with the established role for the RMTg in regulating avoidance behaviors (Meye et al., 2015) . Conversely, photostimulation triggered avoidance of the light-paired chamber in mice expressing opto-MOR in VP GABAergic neurons as expected.
The fact that Cre-inducible opto-MOR can be targeted to discrete populations of neurons, and that MOR-like signaling can be activated specifically in these neurons to modulate behavior in the expected manner, is an important breakthrough. This overcomes one of the major challenges in studying MOR transmission, or indeed the role for any receptor class in the brain, using traditional pharmacological approaches. Even the most selective MOR agonists or antagonists cannot distinguish between MORs expressed at different cellular locations within the same brain structure. For example, MORs expressed both at pre-and postsynaptic sites will be impacted by systemic or even local administration of pharmacological agents that can modulate MOR activity. Hence, opto-MOR and other optogenetically regulated receptors will permit unprecedented deconvolution of receptor signaling dynamics in complex circuits.
KORD and opto-MOR are powerful new tools built on the basic principles of opioid receptor signaling. These exciting tools will open new avenues of research based on the multiplexed control of discrete populations of neurons in a bidirectional manner and more in keeping with the natural signaling dynamics of neuromodulators.
Like most sensory systems, the vertebrate visual system is organized into parallel channels that process distinct aspects of the sensory stimulus. These channels arise in the retina, where local circuitry isolates features of the visual scene such as changes in light level, color, or motion in particular directions. These features are then reported to the brain through the firing patterns of 30 retinal ganglion cell (RGC) types, each of which constitutes a distinct information channel (Sanes and Masland, 2015) . What happens to these channels when they reach the brain remains somewhat murky. Most RGCs project along the optic tract to the lateral geniculate nucleus and/ or the superior colliculus, but there are dozens of additional brain regions that receive RGC inputs-46 in mouse (Morin and Studholme, 2014) . Presumably, if the retina goes to the trouble of parsing information into distinct RGC channels, they should project to distinct targets. For the limited number of RGC types that have been analyzed, we know that their projections are indeed quite specific: they target distinct sublayers of the geniculate and colliculus, and they project to distinct subsets of the minor retinorecipient targets (Baier, 2013; Dhande and Huberman, 2014) . This finding raises the question: what are the molecular mechanisms that determine the specificity of RGC projections? These mechanisms are important because they ensure that each channel of visual information is delivered to a brain region that can make use of it. In this issue of Neuron, two papers tackle this question, uncovering key molecular cues for wiring one particular visual channel, and demonstrating the perceptual consequences when this channel is not wired correctly (Osterhout et al., 2015; Sun et al., 2015) .
The visual pathway addressed in these two papers has a specialized role in detecting full-field motion for the purpose of image stabilization: when the head or body moves, the entire visual image will shift on the retina. Motion, detected by the retina or the inner ear, drives two reflexes-the optokinetic and the vestibuloocular reflexes-that produce compensatory eye movements to keep the image stable and clear. The RGCs that detect image motion for the optokinetic reflex were discovered in the rabbit in the 1960s and have subsequently been identified in most vertebrates (Dhande and Huberman,
